Article
Enhanced activity against syngeneic murine tumors by intrasplenic injection of recombinant interleukin-2 (IL-2) and interleukin-1 (IL-1).
Cancer biotherapy - 1 Jan 1993
Nakajima I, Ozaki M, Jinnai H, Shilayama Y, Hirohata T, Okuno K, Yasutomi M
Abstract excerpt
The antitumor activity of Interleukin-1 (IL-1), was assessed against the murine adenocarcinoma colon 26 tumor model in combination with Interleukin-2 (IL-2). Colon 26 tumor cells were inoculated on the back of syngeneic BALB/c mice. Fourteen days after inoculation, when the tumor nodule reached approximately 10 mm in diameter, tumor nodules were resected and Hank's solution, IL-2, IL-1, or IL-2 plus IL-1 were...
Topics
- Adenocarcinoma
- Animals
- Female
- Immunotherapy
- Interleukin-1
- Interleukin-2
- Killer Cells, Lymphokine-Activated
- Killer Cells, Natural
- Mice
- Mice, Inbred BALB C
- Neoplasm Transplantation